Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells

被引:62
作者
Guo, J
Zhang, MG
Wang, BC
Yuan, ZL
Guo, ZH
Chen, TY
Yu, YZ
Qin, ZH
Cao, XT
机构
[1] Mil Med Univ 2, Inst Immunol, Shanghai 200433, Peoples R China
[2] PLA, Jinan Gen Hosp, Jinan, Peoples R China
关键词
fractalkine; antitumor immunity; dendritic cells; T cells; lung carcinoma;
D O I
10.1002/ijc.10816
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fractalkine (FK, also called neurotactin or CX3CLI) is a CX3C chemokine that can chemoattract T lymphocytes, monocytes and NK cells. In our study, we investigated the induction of antitumor response by FK gene transfer. FK gene-modified 3LL lung carcinoma cells (3LL-FK) could both secrete soluble form and express membrane-bound form of FK. The tumor growth of 3LL-FK was decreased. Vaccination with 3LL-FK was effective in the induction of protective immunity and CTL. In vivo depletion analysis demonstrated that CD8(+) T cells are the main participating cells of the antitumor response. Obvious infiltrations of CD8(+) T cells, CD4(+) T cells and dendritic cells (DC) were observed in the tumor sites, suggesting that 3LL-FK might induce antitumor immunity through chemoattraction and activation of T cells and DC. Then we investigated the chemoattraction and activation of DC by 3LL-FK. Chemotaxis assay showed that the supernatants of 3LL-FK could chemoattract immature DC, which were found to express FK receptor CX3CRI, and the immature DC could obviously adhere to 3LL-FK. Adherence of DC to 3LL-FK resulted in phenotypic maturation and upregulated IL-12 secretion of DC, and more strong stimulation of allogeneic T-cell proliferation by DC. The increased production of IL-2 and IFNgamma in 3LL-FK tumor tissue was also observed. Our data suggested that FK gene transfer to tumor cells could induce T-cell-dependent antitumor immunity through chemoattraction and activation of DC. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:212 / 220
页数:9
相关论文
共 46 条
[31]   RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: Role of immune cell subpopulations [J].
Mule, JJ ;
Custer, M ;
Averbook, B ;
Yang, JC ;
Weber, JS ;
Goeddel, DV ;
Rosenberg, SA ;
Schall, TJ .
HUMAN GENE THERAPY, 1996, 7 (13) :1545-1553
[32]   Involvement of chemokine receptors in breast cancer metastasis [J].
Müller, A ;
Homey, B ;
Soto, H ;
Ge, NF ;
Catron, D ;
Buchanan, ME ;
McClanahan, T ;
Murphy, E ;
Yuan, W ;
Wagner, SN ;
Barrera, JL ;
Mohar, A ;
Verástegui, E ;
Zlotnik, A .
NATURE, 2001, 410 (6824) :50-56
[33]   A candidate for cancer gene therapy: MIP-1 alpha gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice [J].
Nakashima, E ;
Oya, A ;
Kubota, Y ;
Kanada, N ;
Matsushita, R ;
Takeda, K ;
Ichimura, F ;
Kuno, K ;
Mukaida, N ;
Hirose, K ;
Nakanishi, I ;
Ujiie, T ;
Matsushima, K .
PHARMACEUTICAL RESEARCH, 1996, 13 (12) :1896-1901
[34]  
Papadopoulos EJ, 1999, EUR J IMMUNOL, V29, P2551, DOI 10.1002/(SICI)1521-4141(199908)29:08<2551::AID-IMMU2551>3.0.CO
[35]  
2-T
[36]  
Papadopoulos EJ, 2000, EUR J IMMUNOL, V30, P2355, DOI 10.1002/1521-4141(2000)30:8<2355::AID-IMMU2355>3.0.CO
[37]  
2-#
[38]   Chemokines [J].
Rollins, BJ .
BLOOD, 1997, 90 (03) :909-928
[39]   Cloning and characterization of a new type of mouse chemokine [J].
Rossi, DL ;
Hardiman, G ;
Copeland, NG ;
Gilbert, DJ ;
Jenkins, N ;
Zlotnik, A ;
Bazan, JF .
GENOMICS, 1998, 47 (02) :163-170
[40]   Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo [J].
Sharma, S ;
Stolina, M ;
Luo, J ;
Strieter, RM ;
Burdick, M ;
Zhu, LX ;
Batra, RK ;
Dubinett, SM .
JOURNAL OF IMMUNOLOGY, 2000, 164 (09) :4558-4563